Pays
Checkpoint
PubMed
Racine
Checkpoint
PubMed
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Checkpoint (PubMed)

Index « Pays » - entrée « Iran »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Inde < Iran < Irlande (pays)  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 7.
Ident.Authors (with country if any)Title
000038 (2020) Banafsheh Mosharmovahed [Iran] ; Yousef Fatahi [Iran] ; Bahareh Mohebbi [Iran] ; Sohrab Ali Ghorbanian [Iran] ; Sara Assadiasl [Iran]Tocilizumab in transplantation.
000159 (2020) Mohsen Jari [Iran] ; Reza Shiari [Iran] ; Omid Salehpour [Iran] ; Khosro Rahmani [Iran]Epidemiological and advanced therapeutic approaches to treatment of uveitis in pediatric rheumatic diseases: a systematic review and meta-analysis.
000454 (2019) Hassan Yousefi [Iran] ; Majid Momeny [Iran] ; Seyed H. Ghaffari [Iran] ; Nazanin Parsanejad [Iran] ; Arash Poursheikhani [Iran] ; Sepehr Javadikooshesh [Iran] ; Ghazaleh Zarrinrad [Iran] ; Fatemeh Esmaeili [Iran] ; Zivar Alishahi [Iran] ; Zahra Sabourinejad [Iran] ; Ghazaleh Sankanian [Iran] ; Sahar Shamsaiegahkani [Iran] ; Davood Bashash [Iran] ; Narjes Shahsavani [Canada] ; Javad Tavakkoly-Bazzaz [Iran] ; Kamran Alimoghaddam [Iran] ; Ardeshir Ghavamzadeh [Iran]IL-6/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer.
000B26 (2017) Forouhe Zahir-Jouzdani [Iran] ; Fatemeh Atyabi [Iran] ; Nazanin MojtabaviInterleukin-6 participation in pathology of ocular diseases.
000B57 (2017) Arman Ahmadzadeh [Iran] ; Alireza N. Farahmand [Iran] ; Latif Gachkar [Iran]Evaluation of safety, efficacy and post-cessation efficacy durability of tocilizumab in patients with active rheumatoid arthritis.
000E87 (2016) Amir Hashemi-Meshkini [Iran] ; Shekoufeh Nikfar [Iran] ; Elizabeth Glaser [États-Unis] ; Ahmadreza Jamshidi [Iran] ; Seyed Alireza Hosseini [Iran]Cost-Effectiveness Analysis of Tocilizumab in Comparison with Infliximab in Iranian Rheumatoid Arthritis Patients with Inadequate Response to tDMARDs: A Multistage Markov Model.
001028 (2015) Mohammed Hammoudeh [Qatar] ; Adel Al Awadhi [Koweït] ; Eman Haji Hasan [Koweït] ; Maassoumeh Akhlaghi [Iran] ; Arman Ahmadzadeh [Iran] ; Bahar Sadeghi Abdollahi [Iran]Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/AffPays.i -k "Iran" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/AffPays.i  \
                -Sk "Iran" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    indexItem
   |index=    AffPays.i
   |clé=    Iran
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021